查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1701333

罕见疾病临床检测市场规模、份额、趋势分析报告：按阶段、治疗领域、赞助商、地区和细分市场预测，2025 年至 2030 年

Rare Disease Clinical Trials Market Size, Share, & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Therapeutic Area (Oncology, Cardiovascular), By Sponsor, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

罕见疾病临床检测市场的成长与趋势

根据 Grand View Research, Inc. 的最新报告，全球罕见疾病临床检测市场预计到 2030 年将达到 190.2 亿美元，2025 年至 2030 年期间的复合年增长率为 6.8%。

罕见疾病临床检测产业的主要驱动力是全球罕见疾病的沉重负担和日益增长的研究需求。此外，间歇性的产品发布和大量正在筹备的产品也推动了成长。政府鼓励产品开发的措施（例如《孤儿药法案》）预计将进一步促进该产业的发展。

根据美国国立卫生研究院（NIH）的数据，全球有超过7000种罕见疾病。这些疾病影响了约 3000 万美国人，即十分之一的美国人。据 Eurodis 称，72% 的罕见疾病是遗传性的，其余则是感染疾病、过敏性或环境性的。人们对罕见疾病的认识不断提高，对开发治疗罕见疾病的潜在治疗方法的兴趣日益浓厚，预计将支持市场的成长。

製药公司和非营利组织正在积极资助罕见疾病临床研究。例如，2022年2月，卫生研究委员会提供了110万美元的资金，用于支持罕见疾病临床测试。预计未来将继续进行类似的努力，在预测期内为市场提供支援。

近年来，孤儿药的销售额稳定成长。例如，根据Evaluate Pharma的数据，孤儿药销售额将在2020年达到1,380亿美元，并在2022年达到1,720亿美元。预计到2026年孤儿药销售额将达2,680亿美元。罕见疾病治疗药物销售额的成长预计将激发研究人员对开发该领域新疗法的兴趣，从而为疫情后的市场提供支持。

罕见疾病临床检测市场报告重点

  • 到 2024 年，III 期临床试验部分将占据市场主导地位，收入份额将达到 54.2%。由于需要大量志愿者，III 期罕见疾病临床试验成本高昂，推动了这一部分的成长。
  • 2024年，肿瘤学将占据销售额的最大份额。研究人员对开发治疗罕见癌症的新潜在治疗方法的兴趣日益浓厚，这推动了这一领域的成长。
  • 由于非营利组织提供大量资金支持罕见疾病临床研究，预计预测期内非营利组织部门将以显着的复合年增长率成长。
  • 到2024年，北美将占据市场主导地位，销售额占比达42.6%。北美罕见疾病发生率高以及临床检测领域公司数量众多是其市场占有率高的主要原因。

目录

第一章调查方法与范围

第二章执行摘要

3. 罕见疾病临床检测市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析

第四章罕见疾病临床检测市场：阶段业务分析

  • 2024年及2030年的阶段市场占有率
  • 阶段细分仪表板
  • 市场规模、预测与趋势分析（分阶段，2018-2030年）
  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

第五章罕见疾病临床测试市场：治疗领域商业分析

  • 2024 年和 2030 年治疗领域市场占有率
  • 治疗领域细分仪表板
  • 按治疗领域分類的市场规模、预测和趋势分析（2018-2030 年）
  • 肿瘤学
  • 心血管疾病
  • 神经系统疾病
  • 感染疾病
  • 遗传性疾病
  • 自体免疫和炎症
  • 血液系统疾病
  • 肌肉骨骼疾病
  • 其他的

第六章 罕见疾病临床试验市场：申办方业务分析

  • 2024年和2030年的赞助市场占有率
  • 赞助细分仪表板
  • 市场规模、预测和趋势分析（按赞助商，2018-2030 年）
  • 製药和生物製药公司
  • 非营利组织
  • 其他的

第七章：罕见疾病临床检测市场：按地区估计和趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018-2030年市场规模及预测趋势分析
  • 北美洲
    • 2018-2030年各国情况
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 2018-2030年各国情况
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 2018-2030年各国情况
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 2018-2030年各国情况
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章竞争格局

  • 参与者概述
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Takeda Pharmaceutical Company Limited
    • F. Hoffmann-La Roche Ltd
    • Pfizer Inc
    • AstraZeneca
    • Novartis AG
    • Laboratory Corporation of America Holdings（LabCorp）
    • IQVIA
    • Charles River Laboratories
    • ICON plc
    • Parexel International（MA）Corporation
Product Code: GVR-4-68040-031-1

Rare Disease Clinical Trials Market Growth & Trends:

The global rare disease clinical trials market size is expected to reach USD 19.02 billion by 2030, expanding at 6.8% CAGR from 2025 to 2030, according to a new report by Grand View Research, Inc. The main driving factors of the rare disease clinical trial industry are the high burden of rare diseases worldwide, which has led to rising demand for research. Furthermore, intermittent launches and a large number of products in the pipeline also propel growth. Government initiatives that encourage product development, such as the Orphan Drug Act, are further expected to assist industry growth.

According to the National Institutes of Health (NIH), there are more than 7,000 rare diseases worldwide. These diseases affect nearly 30 million Americans, or 1 in every 10 people. Eurodis states that 72% of rare diseases are genetic, while others are caused by infections, allergies, and environmental causes. The growing awareness among people regarding rare diseases and growing interest in developing potential treatments for treating rare diseases are expected to support market growth.

Pharmaceutical companies and non-profit organizations are actively providing funding for rare disease clinical research. For instance, in February 2022, the Health Research Board funded USD 1.1 million to support rare disease clinical trials. Similar initiatives in the future are expected to support the market during the forecast period.

Orphan drug sales have been steadily increasing in recent years. For instance, according to Evaluate Pharma, orphan drug sales accounted for USD 138 billion in 2020, and by 2022, they accounted for USD 172 billion. It is estimated that orphan drug sales will reach USD 268 billion by 2026. The rise in the sales of orphan drugs is expected to generate interest among researchers in developing new treatments in the area of rare diseases and thus support the market in the post-pandemic period.

Rare Disease Clinical Trials Market Report Highlights:

  • The phase III segment dominated the market with the largest revenue share of 54.2% in 2024. The segment's growth is supported by the high cost of phase III rare disease clinical trials due to the requirement for a large number of volunteers
  • The oncology segment dominated the market with the largest revenue share in 2024. The growing interest of researchers in the development of new potential treatments for treating rare cancers is supporting the growth of the segment
  • The non-profit organizations segment is projected to grow at a significant CAGR over the forecast period owing to the significant funding offered by these organizations to support rare disease clinical research
  • North America dominated the market and accounted for a revenue share of 42.6% in 2024. The high burden of rare diseases in North America and the presence of a large number of players in clinical trials are some of the key reasons for its high market share

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Phase
    • 1.2.2. Therapeutic Area
    • 1.2.3. Sponsor
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Rare Disease Clinical Trials Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Rare Disease Clinical Trials Market: Phase Business Analysis

  • 4.1. Phase Market Share, 2024 & 2030
  • 4.2. Phase Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Phase, 2018 to 2030 (USD Billion)
  • 4.4. Phase I
    • 4.4.1. Phase I Market, 2018 - 2030 (USD Billion)
  • 4.5. Phase II
    • 4.5.1. Phase II Market, 2018 - 2030 (USD Billion)
  • 4.6. Phase III
    • 4.6.1. Phase II Market, 2018 - 2030 (USD Billion)
  • 4.7. Phase IV
    • 4.7.1. Phase IV Market, 2018 - 2030 (USD Billion)

Chapter 5. Rare Disease Clinical Trials Market: Therapeutic Area Business Analysis

  • 5.1. Therapeutic Area Market Share, 2024 & 2030
  • 5.2. Therapeutic Area Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Billion)
  • 5.4. Oncology
    • 5.4.1. Oncology Market, 2018 - 2030 (USD Billion)
  • 5.5. Cardiovascular Disorders
    • 5.5.1. Cardiovascular Disorders Market, 2018 - 2030 (USD Billion)
  • 5.6. Neurological Disorders
    • 5.6.1. Neurological Disorders Market, 2018 - 2030 (USD Billion)
  • 5.7. Infectious Disease
    • 5.7.1. Infectious Disease Market, 2018 - 2030 (USD Billion)
  • 5.8. Genetic Disorders
    • 5.8.1. Genetic Disorders Market, 2018 - 2030 (USD Billion)
  • 5.9. Autoimmune and Inflammation
    • 5.9.1. Autoimmune and Inflammation Market, 2018 - 2030 (USD Billion)
  • 5.10. Hematologic Disorders
    • 5.10.1. Hematologic Disorders Market, 2018 - 2030 (USD Billion)
  • 5.11. Musculoskeletal Disorders
    • 5.11.1. Musculoskeletal Disorders Market, 2018 - 2030 (USD Billion)
  • 5.12. Others
    • 5.12.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 6. Rare Disease Clinical Trials Market: Sponsor Business Analysis

  • 6.1. Sponsor Market Share, 2024 & 2030
  • 6.2. Sponsor Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Sponsor, 2018 to 2030 (USD Billion)
  • 6.4. Pharmaceutical & Biopharmaceutical Companies
    • 6.4.1. Pharmaceutical & Biopharmaceutical Companies Market, 2018 - 2030 (USD Billion)
  • 6.5. Non-Profit Organizations
    • 6.5.1. Non-Profit Organizations Market, 2018 - 2030 (USD Billion)
  • 6.6. Other
    • 6.6.1. Other Market, 2018 - 2030 (USD Billion)

Chapter 7. Rare Disease Clinical Trials Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Rare Disease Clinical Trials Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5. Europe
    • 7.5.1. Europe Rare Disease Clinical Trials Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Denmark Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Sweden Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Norway Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.7. Latin America
    • 7.7.1. Latin America Rare Disease Clinical Trials Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.8. MEA
    • 7.8.1. MEA Rare Disease Clinical Trials Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Takeda Pharmaceutical Company Limited
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. F. Hoffmann-La Roche Ltd
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Pfizer Inc
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. AstraZeneca
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Novartis AG
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Laboratory Corporation of America Holdings (LabCorp)
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. IQVIA
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Charles River Laboratories
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. ICON plc
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Parexel International (MA) Corporation
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global rare disease clinical trials market, by region, 2018 - 2030 (USD Billion)
  • Table 4. Global rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 5. Global rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 6. Global rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 7. North America rare disease clinical trials market, by country, 2018 - 2030 (USD Billion)
  • Table 8. North America rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 9. North America rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 10. North America rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 11. U.S. rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 12. U.S. rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 13. U.S. rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 14. Canada rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 15. Canada rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 16. Canada rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 17. Mexico rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 18. Mexico rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 19. Mexico rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 20. Europe rare disease clinical trials market, by country, 2018 - 2030 (USD Billion)
  • Table 21. Europe rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 22. Europe rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 23. Europe rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 24. UK rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 25. UK rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 26. UK rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 27. Germany rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 28. Germany rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 29. Germany rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 30. France rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 31. France rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 32. France rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 33. Italy rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 34. Italy rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 35. Italy rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 36. Spain rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 37. Spain rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 38. Spain rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 39. Denmark rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 40. Denmark rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 41. Denmark rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 42. Sweden rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 43. Sweden rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 44. Sweden rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 45. Norway rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 46. Norway rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 47. Norway rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 48. Asia Pacific rare disease clinical trials market, by country, 2018 - 2030 (USD Billion)
  • Table 49. Asia Pacific rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 50. Asia Pacific rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 51. Asia Pacific rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 52. Japan rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 53. Japan rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 54. Japan rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 55. China rare disease clinical trials market, by phase, 2018-2030 (USD Billion)
  • Table 56. China rare disease clinical trials market, by therapeutic area, 2018-2030 (USD Billion)
  • Table 57. China rare disease clinical trials market, by sponsor, 2018-2030 (USD Billion)
  • Table 58. India rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 59. India rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 60. India rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 61. South Korea rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 62. South Korea rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 63. South Korea rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 64. Australia rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 65. Australia rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 66. Australia rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 67. Thailand rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 68. Thailand rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 69. Thailand rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 70. Latin America rare disease clinical trials market, by country, 2018 - 2030 (USD Billion)
  • Table 71. Latin America rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 72. Latin America rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion
  • Table 73. Latin America rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion
  • Table 74. Brazil rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 75. Brazil rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 76. Brazil rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 77. Argentina rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 78. Argentina rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 79. Argentina rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 80. Middle East & Africa rare disease clinical trials market, by country, 2018 - 2030 (USD Billion)
  • Table 81. Middle East & Africa rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 82. Middle East & Africa rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 83. Middle East & Africa rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 84. South Africa rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 85. South Africa rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 86. South Africa rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 87. Saudi Arabia rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 88. Saudi Arabia rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 89. Saudi Arabia rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 90. UAE rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 91. UAE rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 92. UAE rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 93. Kuwait rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 94. Kuwait rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 95. Kuwait rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Rare disease clinical trials market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Phase outlook (USD Billion)
  • Fig. 10 Therapeutic area outlook (USD Billion)
  • Fig. 11 Sponsor outlook (USD Billion)
  • Fig. 12 Competitive landscape
  • Fig. 13 Rare disease clinical trials market dynamics
  • Fig. 14 Rare disease clinical trials market: Porter's five forces analysis
  • Fig. 15 Rare disease clinical trials market: PESTLE analysis
  • Fig. 16 Rare disease clinical trials market: Phase segment dashboard
  • Fig. 17 Rare disease clinical trials market: Phase market share analysis, 2024 & 2030
  • Fig. 18 Phase I market, 2018 - 2030 (USD Billion)
  • Fig. 19 Phase II market, 2018 - 2030 (USD Billion)
  • Fig. 20 Phase III market, 2018 - 2030 (USD Billion)
  • Fig. 21 Phase IV market, 2018 - 2030 (USD Billion)
  • Fig. 22 Rare disease clinical trials market: Therapeutic area segment dashboard
  • Fig. 23 Rare disease clinical trials market: Therapeutic area market share analysis, 2024 & 2030
  • Fig. 24 Oncology market, 2018 - 2030 (USD Billion)
  • Fig. 25 Cardiovascular disorders market, 2018 - 2030 (USD Billion)
  • Fig. 26 Neurological disorders market, 2018 - 2030 (USD Billion)
  • Fig. 27 Infectious disease market, 2018 - 2030 (USD Billion)
  • Fig. 28 Genetic disorders market, 2018 - 2030 (USD Billion)
  • Fig. 29 Autoimmune and inflammation market, 2018 - 2030 (USD Billion)
  • Fig. 30 Hematologic disorders market, 2018 - 2030 (USD Billion)
  • Fig. 31 Musculoskeletal disorders market, 2018 - 2030 (USD Billion)
  • Fig. 32 Others market, 2018 - 2030 (USD Billion)
  • Fig. 33 Rare disease clinical trials market: Sponsor segment dashboard
  • Fig. 34 Rare disease clinical trials market: Sponsor market share analysis, 2024 & 2030
  • Fig. 35 Pharmaceutical & biopharmaceutical companies market, 2018 - 2030 (USD Billion)
  • Fig. 36 Non-profit organizations market, 2018 - 2030 (USD Billion)
  • Fig. 37 Other market, 2018 - 2030 (USD Billion)
  • Fig. 38 Rare disease clinical trials market revenue, by region
  • Fig. 39 Regional marketplace: Key takeaways
  • Fig. 40 North America rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 41 U.S. country dynamics
  • Fig. 42 U.S. rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 43 Canada country dynamics
  • Fig. 44 Canada rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 45 Mexico country dynamics
  • Fig. 46 Mexico rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 47 Europe rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 48 UK country dynamics
  • Fig. 49 UK rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 50 Germany country dynamics
  • Fig. 51 Germany rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 52 France country dynamics
  • Fig. 53 France rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 54 Italy country dynamics
  • Fig. 55 Italy rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 56 Spain country dynamics
  • Fig. 57 Spain rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 58 Denmark country dynamics
  • Fig. 59 Denmark rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 60 Sweden country dynamics
  • Fig. 61 Sweden rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 62 Norway country dynamics
  • Fig. 63 Norway rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 64 Asia Pacific rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 65 Japan country dynamics
  • Fig. 66 Japan rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 67 China country dynamics
  • Fig. 68 China rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 69 India country dynamics
  • Fig. 70 India rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 71 South Korea country dynamics
  • Fig. 72 South Korea rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 73 Australia country dynamics
  • Fig. 74 Australia rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 75 Thailand country dynamics
  • Fig. 76 Thailand rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 77 Latin America rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 78 Brazil country dynamics
  • Fig. 79 Brazil rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 80 Argentina country dynamics
  • Fig. 81 Argentina rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 82 MEA rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 83 South Africa country dynamics
  • Fig. 84 South Africa rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 85 Saudi Arabia country dynamics
  • Fig. 86 Saudi Arabia rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 87 UAE country dynamics
  • Fig. 88 UAE rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 89 Kuwait country dynamics
  • Fig. 90 Kuwait rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 91 Company categorization
  • Fig. 92 Company market position analysis
  • Fig. 93 Strategic framework